LB Pharmaceuticals presents data on LB-102 at ECNP congress

LB Pharmaceuticals Inc (NASDAQ:LBRX) exhibited four posters detailing its research on LB-102 at the 39th European College of Neuropsychopharmacology Congress in Munich, Germany. The presentations covered the drug's mechanism of action, pivotal Phase 3 trials for schizophrenia and bipolar depression, cognitive performance in schizophrenia, and ongoing trials.

The preclinical study illustrated that LB-102 can modulate dopamine signaling in rat nucleus accumbens by engaging pre-synaptic D2 autoreceptors. This action increases dopamine neurotransmission by attenuating autoreceptor-mediated inhibition of dopamine release. A poster showcased dose-dependent improvements in the Global Cognition composite score from the Phase 2 NOVA-1 trial in schizophrenia patients, with the post hoc analysis concluding that the cognitive benefit was a direct effect of LB-102.

The company unveiled details of its ongoing pivotal Phase 3 NOVA-2 trial and open label extension NOVA-3 trial, which aim to assess LB-102's efficacy, safety, and long-term effectiveness as a once-daily treatment for adults with schizophrenia. An e-poster introduced the design of the ongoing Phase 2 ILLUMINATE-1 trial, examining LB-102's efficacy and safety in adults with bipolar depression when used as monotherapy.

LB-102 is a small molecule under development for various neuropsychiatric disorders, and the company revealed positive data from a Phase 2 schizophrenia trial in early 2025.